Call Us Contact Us
+44 1494 818 000     Online Enquiry
Lines open
Monday to Thursday
08:30 to 18:00
08:30 to 17:30
Pharmaceutical | Medical Devices | Scientific | Consumer Healthcare | Dental | Animal Health
Healthcare Communications | Pharmaceutical Executive | Medical Executive | Tech PR | Scientific Executive
Latest Jobs
Exclusive vacancies may not be shown here, please contact Laura on +44 1494 818 026 or for more information.
Have you registered?
Once you register you can see additional job details, save jobs, track your applications and manage e-lert preferences.

Register now
Laura Marsh
Account Manager
+44 1494 818 026

I have really enjoyed my time with Zenopa so far. There has been continuous training and support. I've developed stronger communications.
Laura, 2014

Merck Sharp and Dohme reports positive Isentress data

23 July 2012 11:36 in Pharmaceutical Company Product News

Merck Sharp and Dohme has reported positive data from a new long-term clinical study of Isentress, its approved treatment for HIV-1 infection among adult patients.

Final results from the STARTMRK trial have demonstrated that the compound is able to deliver efficacy, safety and tolerability for previously untreated adult patients with HIV-1 for up to 240 weeks.

At all pre-specified time points, the regimen containing Isentress had fewer drug-related adverse events versus the comparison group, while generating better viral suppression and a greater immunologic response.

Dr Daria Hazuda, worldwide head of antiviral basic research at Merck Sharp and Dohme and lead scientist for Isentress, said: "After more than 25 years of leadership in HIV research, we remain dedicated to conducting comprehensive research to help address the real-world needs of people living with HIV."

This comes after the firm presented encouraging data from clinical and preclinical Alzheimer's drug trials at the Alzheimer's Association International Conference last week.ADNFCR-8000103-ID-801412799-ADNFCR

Other news stories from 23/07/2012

Related news

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Axonn News Agency

© Copyright 2014 Zenopa Ltd